Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER trial Report uri icon

Overview

MeSH Major

  • Gene Expression Profiling
  • Genomics
  • Models, Statistical
  • Neoplasms, Germ Cell and Embryonal

abstract

  • Metastatic germ cell tumours (GCTs) are usually cured with cisplatin based chemotherapy and standard treatment algorithms are established. However when this treatment fails and the disease relapses, standard treatment is much more uncertain. Both conventional dose therapy (CDT) and high dose therapy (HDT) are widely used, due to the lack of conclusive data supporting one specific approach. A recent retrospective analysis focusing on this population suggested a significant benefit for HDT. Retrospective analyses are prone to bias, and therefore while this data is provocative it is by no mean conclusive. For this reason the international community is supporting a prospective randomised trial in this area comparing CDT(TIP) with sequential HDT (TICE). The planned open labelled randomised phase III study (TIGER) is due to open in 2011 and will recruit 390 patients to detect a 13% difference in 2 year progression free survival (primary endpoint). It is hoped that this large study will conclusively resolve the uncertainty which currently exists.

publication date

  • December 2011

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.7150/jca.2.374

Additional Document Info

start page

  • 374

end page

  • 7

volume

  • 2

number

  • 1